← All Tiziana Life Sciences LTD filings

Tiziana Life Sciences LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
TLSA
Tiziana Life Sciences LTD
20-F: Tiziana Life Sciences 2025 Annual Report Analysis
Tiziana Life Sciences reports progress in its intranasal Foralumab clinical pipeline for neurodegenerative diseases while highlighting going concern risks.
NASDAQ
TLSA
Tiziana Life Sciences LTD
20-F/A: Tiziana Life Sciences Amends 20-F, Highlights Clinical Program and Corrects Exhibit Numbers
Tiziana Life Sciences files an amendment to its 20-F report to include recent clinical program updates and correct exhibit numbers.
NASDAQ
TLSA
Tiziana Life Sciences LTD
20-F: Tiziana Life Sciences Reports 2024 Financials, Advances Foralumab in Neurodegenerative Disease Trials Amidst Funding Needs and Governance Disclosures
Tiziana Life Sciences Ltd has released its 2024 annual report, detailing a net loss of $12.0 million and significant progress with its lead candidate Foralumab for MS and Alzheimer's, while also highlighting a going concern uncertainty and a material weakness in internal controls.
NASDAQ
TLSA
Tiziana Life Sciences LTD
20-F: Tiziana Life Sciences Reports Full Year 2023 Results and Provides Business Update
Tiziana Life Sciences Ltd reports its financial results for the year ended December 31, 2023, and provides an update on its clinical development programs, focusing on intranasal foralumab for neurodegenerative diseases.